GBA Presents: RADIO SAVANT-!

BJ GOLDEN CROSS--

BJ's Wholesale Club Holdings, Inc. (BJ) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BJ's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."
 
The bullish case only gets stronger once investors take into account BJ's positive earnings outlook for the current quarter. There have been 2 upwards revisions compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.

4137f088b815b8b218567bd0e6a1d99b

Moving Average Chart for BJ There is the slap and tickle phase, the re-boot,
the second erection and the finish.
 
vanzandt said:
I think this market is gearing up for a nice correction.
Every chart I'm looking at, the quality stuff, all look too good.
That usually precludes a market-wide drop.
4085 is a key level to watch imo.
More...
WOW!!!
Before he left The Walrus left the children with this gift.
Nailed a major pivot point within 5 points.
How does he do it Stoney?!
 
Stoney!!!
You don't need a BJ, you need The Virgin.

4000 red stocks... and The Virgin is in the green.

SPCE---> $6.19 (+3%) :wtf:


Cuuuu-Cuuuu-Keee-Choo.
 
Stoney!!!

It looks like Sir VZ of Radio Savant fame has brought SPCE to the Robinhooders and WSB'ers.
The kind of research found nowhere else.

vanzandt said:
It looks like State Street and Vangaurd took large positions in Virgin Galactic.
14% of the company.
Hmmmm.
SPCE--->$4.90
More...

vanzandt said:
Hmmm. Now I see there were 23 block trades on this thing today.
1/2 million shares.
That's not retail.

I wonder if Sir Richard's little space stock is readying for launch again?
It got as high as $60 back in the heyday.
Was this a spac?

Virgin Galactic
$SPCE -->$5.00

Hmmmm.
More...

vanzandt said:
Hey speaking of block trades, I just checked on SPCE again.... there were 41 today.
1.1 million shares.
17% of today's volume.
Something is brewing with this stock.
I wonder what Sir Richard is up to... (?)
More...

See what you miss Stoney, is the Children love moxy... and Sir Richard is the King of Moxy.
GME is dead. Bed & Bath... dead..... there's only ONE stock that The Children will take what remains of their Robinhood accounts and go all in on and that stock is>>> The Virgin.

Space Stoney!
"The final frontier."
Sir Richard will save the world... by saving the younger generation's brokerage accounts.
Buy The Virgin!!!!
$6.19
 
stonedinvestor said:
Natura &Co upgraded to Buy from Neutral at BofA <-----

STOCK OF THE DAY-- NTRA

Natera, Inc.(NTRA)

We’ll start with Natera, a biotech company operating in the cell-free DNA testing niche, or cfDNA. cfDNA tests are minimally invasive, based on a simple blood draw, and focus on naturally occurring DNA fragments that float freely in the bloodstream. Natera’s technology captures those fragments and uses them for genetic testing.

The company’s testing platforms are based on novel molecular biology techniques and AI driven bioinformatics software, and can detect single DNA molecules in a blood sample tube. Natera uses this technology for accurate, non-invasive prenatal testing (the Panorama platform), tumor-specific assay testing for individualized cancer treatments (the Signatera platform), and best-in-class rejection assessment testing prior to kidney transplantation (the Prospera platform).

Diagnostic DNA testing is big business, and Natera is capitalizing on patients’ desire for a less invasive medical experience. The company’s revenues have been showing steady growth for the past several years, and in the last reported quarter, 3Q22, Natera saw a top line of $210.6 million, up 33% year-over-year. The revenue gain came on top of a 27% increase in processed tests during 3Q22, from 407,300 to 517,500. Of that total, the oncology segment saw the strongest growth; the company processed 53,000 oncology tests in the quarter, for a 153% y/y increase.

Natera revised its forward guidance upward in the Q3 report, projecting full-year 2022 revenue of $810 million to $830 million. This was up $40 million at the midline from the previously published guidance. The company is expected to report the 4Q22 results late in February, and we’ll find out then how the guidance holds up.

Joining the bulls, Raymond James' Andrew Cooper takes an upbeat stance on this company and its stock.

"With each of its segments growing nicely in the near- and intermediate-terms and a catalyst rich setup in 2023, particularly in oncology, we are upgrading shares to Outperform. Leadership in the burgeoning MRD space, where we think it can win additional coverage and potentially guideline inclusion at least for CRC, generates the excitement, while an increasingly profitable women’s health business has its own catalysts in conversation around 22q. This all comes at a valuation that looks, at least on a relative basis, reasonably accommodative all things considered," the analyst opined.

Cooper's Outperform (i.e. Buy) rating on NTRA comes with a $58 price target, which implies a one-year upside potential of 35%.

Overall, this interesting biotech has picked up 9 recent analyst reviews, including 8 Buys against a single Hold – for a Strong Buy consensus rating. The shares are trading for $42.94 and their average price target, at $63,
More...




GBA NTRA Natera, Inc.

$49.407.06 (+16.67%)<------------------
 
One of my oldest positions got bought today!

Travel Centers Of America.

I am proud of myself.

It was presented several times to me as a sell out of my account and I held on.

Now would be a good time to insert a large position of something.
 
You must log in or register to reply here.
Back
Top